Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept

Fig. 3

Time to achievement of secondary disease outcomes. A CDAI LDA (≤ 10); B CDAI remission (≤ 2.8); C SDAI remission (≤ 3.3); D DAS28-CRP LDA (< 3.2); E DAS28-CRP remission (< 2.6); F RAPID3 LDA (≤ 6); G RAPID3 remission (≤ 3); H HAQ-DI Δ ≥ 0.22. P-values are based on the log-rank test. Crosses indicate censoring. CDAI: Clinical Disease Activity Index; CI: confidence interval; DAS28-CRP: Disease Activity Score 28-C-reactive protein; HAQ-DI: Health Assessment Questionnaire-Disability Index; LDA: low disease activity; MCID: minimum clinically important difference; RAPID3: Routine Assessment of Patient Index Data 3; RC: routine care; SDAI: Simple Disease Activity Index; SE: standard error; T2T: treat-to-target

Back to article page